益气生血汤治疗急性髓系白血病化疗后骨髓抑制临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R733.7

基金项目:


Clinical Study on Yiqi Shengxue Decoction for Myelosuppression After Chemotherapy for Acute Myeloid Leukemia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察益气生血汤治疗急性髓系白血病(AML) 化疗后骨髓抑制的临床效果。方法:选取 62例AML化疗后骨髓抑制患者,按随机数字表法分为对照组和观察组各31例。2组均采取DA化疗方案,对照 组化疗后给予重组人粒细胞集落刺激因子注射液治疗,观察组化疗后在对照组基础上给予益气生血汤治疗, 2组均以3周为1个疗程,连续治疗3个疗程。评价2组临床疗效,比较2组中医证候积分、血常规指标、骨髓 抑制发生时间、骨髓抑制恢复时间及免疫功能。结果:观察组总有效率为93.55%,高于对照组74.19% (P< 0.05)。治疗后,2组中医证候积分较治疗前降低(P<0.05),且观察组中医证候积分低于对照组(P<0.05)。 治疗后,2组血红蛋白(Hb)、白细胞计数(WBC)、中性粒细胞(NEUT)、血小板(BPC) 水平较治疗前升 高(P<0.05),且观察组Hb、WBC、NEUT、BPC水平高于对照组(P<0.05)。与对照组比较,观察组骨髓抑 制发生时间较晚,骨髓抑制恢复时间较早(P<0.05)。观察组治疗前后免疫功能各项指标比较,差异无统计学 意义(P>0.05)。治疗后,对照组CD3+、CD4+、CD4+/CD8+较治疗前均降低,CD8+较治疗前升高(P<0.05); 观察组治疗后CD3+、CD4+、CD4+/CD8+高于对照组,CD8+低于对照组(P<0.05)。结论:益气生血汤治疗AML 化疗后骨髓抑制有助于缓解患者症状体征,改善血常规指标,延缓骨髓抑制发生时间,促进骨髓抑制恢复,保 护患者机体免疫功能。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Yiqi Shengxue Decoction on myelosuppression after chemotherapy for acute myeloid leukemia (AML). Methods: A total of 62 cases of patients with myelosuppression after chemotherapy for AML were selected and divided into the control group and the observation group according to the random number table method, with 31 cases in each group. Both groups were treated with DA chemotherapy. After chemotherapy, the control group was treated with recombinant human granulocyte colony-stimulating factor injection, and the observation group was additionally treated with Yiqi Shengxue Decoction based on the treatment of the control group. Both groups were treated for three consecutive courses, with three weeks being a course . The clinical effects in the two groups were evaluated; traditional Chinese medicine syndrome scores, blood routine indexes, the occurrence time of myelosuppression, the recovery time of myelosuppression and the immune function were compared between the two groups. Results:The total effective rate was 93.55% in the observation group, higher than that of 74.19% in the control group (P<0.05). After treatment, traditional Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment (P<0.05), and the traditional Chinese medicine syndrome score in the observation group was lower than that in the control group (P<0.05). After treatment,the levels of hemoglobin (Hb),white blood cell count (WBC),neutrophil (NEUT) and blood platelet count (BPC) in the two groups were increased when compared with those before treatment (P<0.05), and the levels of Hb, WBC, NEUT and BPC in the observation group were higher than those in the control group (P<0.05). When compared with those in the control group, the occurrence time of myelosuppression in the observation group was relatively late, and the recovery time of myelosuppression was relatively early (P<0.05). There was no significant difference in immune function indexes in the observation group before and after treatment (P>0.05). After treatment, CD3+ , CD4+ and CD4+/CD8+ in the control group were decreased when compared with those before treatment, and CD8+ levels were increased when compared with those before treatment (P<0.05). After treatment,CD3+,CD4+ and CD4+/CD8+ in the observation group were higher than those in control group, and CD8+ was lower than that in the control group (P<0.05). Conclusion: Yiqi Shengxue Decoction for myelosuppression after chemotherapy for AML can alleviate the symptoms and signs of patients,improve blood routine indexes, delay the occurrence time of myelosuppression, promote the recovery of myelosuppression,and protect the immune function of patients.

    参考文献
    相似文献
    引证文献
引用本文

黄静,徐燕霞,杨晶晶.益气生血汤治疗急性髓系白血病化疗后骨髓抑制临床研究[J].新中医,2024,56(13):194-198

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-07-10
  • 出版日期:
文章二维码